FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896600605> ?p ?o ?g. }

• W2896600605 endingPage "e0006830" @default.
• W2896600605 startingPage "e0006830" @default.
• W2896600605 abstract "In 2010, WHO recommended the use of new short-course treatment regimens in kala-azar elimination efforts for the Indian subcontinent. Although phase 3 studies have shown excellent results, there remains a lack of evidence on a wider treatment population and the safety and effectiveness of these regimens under field conditions.This was an open label, prospective, non-randomized, non-comparative, multi-centric trial conducted within public health facilities in two highly endemic districts and a specialist referral centre in Bihar, India. Three treatment regimens were tested: single dose AmBisome (SDA), concomitant miltefosine and paromomycin (Milt+PM), and concomitant AmBisome and miltefosine (AmB+Milt). Patients with complicated disease or significant co-morbidities were treated in the SDA arm. Sample sizes were set at a minimum of 300 per arm, taking into account inter-site variation and an estimated failure risk of 5% with 5% precision. Outcomes of drug effectiveness and safety were measured at 6 months. The trial was prospectively registered with the Clinical Trials Registry India: CTRI/2012/08/002891.Out of 1,761 patients recruited, 50.6% (n = 891) received SDA, 20.3% (n = 358) AmB+Milt and 29.1% (n = 512) Milt+PM. In the ITT analysis, the final cure rates were SDA 91.4% (95% CI 89.3-93.1), AmB+Milt 88.8% (95% CI 85.1-91.9) and Milt+PM 96.9% (95% CI 95.0-98.2). In the complete case analysis, cure rates were SDA 95.5% (95% CI 93.9-96.8), AmB+Milt 95.5% (95% CI 92.7-97.5) and Milt+PM 99.6% (95% CI 98.6-99.9). All three regimens were safe, with 5 severe adverse events in the SDA arm, two of which were considered to be drug related.All regimens showed acceptable outcomes and safety profiles in a range of patients under field conditions. Phase IV field-based studies, although extremely rare for neglected tropical diseases, are good practice and an important step in validating the results of more restrictive hospital-based studies before widespread implementation, and in this case contributed to national level policy change in India.Clinical trial is registered at Clinical trial registry of India (CTRI/2012/08/002891, Registered on 16/08/2012, Trial Registered Prospectively)." @default.
• W2896600605 created "2018-10-26" @default.
• W2896600605 creator A5001588862 @default.
• W2896600605 creator A5002703410 @default.
• W2896600605 creator A5024500372 @default.
• W2896600605 creator A5024850753 @default.
• W2896600605 creator A5027589913 @default.
• W2896600605 creator A5029032575 @default.
• W2896600605 creator A5029274175 @default.
• W2896600605 creator A5041516138 @default.
• W2896600605 creator A5047505948 @default.
• W2896600605 creator A5056783375 @default.
• W2896600605 creator A5060251393 @default.
• W2896600605 creator A5070984672 @default.
• W2896600605 creator A5071401857 @default.
• W2896600605 creator A5073795408 @default.
• W2896600605 creator A5074357118 @default.
• W2896600605 creator A5082622069 @default.
• W2896600605 creator A5083165391 @default.
• W2896600605 creator A5083176889 @default.
• W2896600605 creator A5089977139 @default.
• W2896600605 creator A5091252310 @default.
• W2896600605 date "2018-10-22" @default.
• W2896600605 modified "2023-10-12" @default.
• W2896600605 title "Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India" @default.
• W2896600605 cites W1985704586 @default.
• W2896600605 cites W1996094668 @default.
• W2896600605 cites W2066680067 @default.
• W2896600605 cites W2072809427 @default.
• W2896600605 cites W2084752824 @default.
• W2896600605 cites W2100756689 @default.
• W2896600605 cites W2101676950 @default.
• W2896600605 cites W2107915297 @default.
• W2896600605 cites W2111222818 @default.
• W2896600605 cites W2120603638 @default.
• W2896600605 cites W2148707789 @default.
• W2896600605 cites W2158168571 @default.
• W2896600605 cites W2620097584 @default.
• W2896600605 doi "https://doi.org/10.1371/journal.pntd.0006830" @default.
• W2896600605 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6197645" @default.
• W2896600605 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30346949" @default.
• W2896600605 hasPublicationYear "2018" @default.
• W2896600605 type Work @default.
• W2896600605 sameAs 2896600605 @default.
• W2896600605 citedByCount "17" @default.
• W2896600605 countsByYear W28966006052019 @default.
• W2896600605 countsByYear W28966006052020 @default.
• W2896600605 countsByYear W28966006052021 @default.
• W2896600605 countsByYear W28966006052022 @default.
• W2896600605 countsByYear W28966006052023 @default.
• W2896600605 crossrefType "journal-article" @default.
• W2896600605 hasAuthorship W2896600605A5001588862 @default.
• W2896600605 hasAuthorship W2896600605A5002703410 @default.
• W2896600605 hasAuthorship W2896600605A5024500372 @default.
• W2896600605 hasAuthorship W2896600605A5024850753 @default.
• W2896600605 hasAuthorship W2896600605A5027589913 @default.
• W2896600605 hasAuthorship W2896600605A5029032575 @default.
• W2896600605 hasAuthorship W2896600605A5029274175 @default.
• W2896600605 hasAuthorship W2896600605A5041516138 @default.
• W2896600605 hasAuthorship W2896600605A5047505948 @default.
• W2896600605 hasAuthorship W2896600605A5056783375 @default.
• W2896600605 hasAuthorship W2896600605A5060251393 @default.
• W2896600605 hasAuthorship W2896600605A5070984672 @default.
• W2896600605 hasAuthorship W2896600605A5071401857 @default.
• W2896600605 hasAuthorship W2896600605A5073795408 @default.
• W2896600605 hasAuthorship W2896600605A5074357118 @default.
• W2896600605 hasAuthorship W2896600605A5082622069 @default.
• W2896600605 hasAuthorship W2896600605A5083165391 @default.
• W2896600605 hasAuthorship W2896600605A5083176889 @default.
• W2896600605 hasAuthorship W2896600605A5089977139 @default.
• W2896600605 hasAuthorship W2896600605A5091252310 @default.
• W2896600605 hasBestOaLocation W28966006051 @default.
• W2896600605 hasConcept C126125632 @default.
• W2896600605 hasConcept C126322002 @default.
• W2896600605 hasConcept C16685009 @default.
• W2896600605 hasConcept C168563851 @default.
• W2896600605 hasConcept C203014093 @default.
• W2896600605 hasConcept C2776555147 @default.
• W2896600605 hasConcept C2778689377 @default.
• W2896600605 hasConcept C2781087480 @default.
• W2896600605 hasConcept C2781417161 @default.
• W2896600605 hasConcept C2908647359 @default.
• W2896600605 hasConcept C535046627 @default.
• W2896600605 hasConcept C71924100 @default.
• W2896600605 hasConcept C99454951 @default.
• W2896600605 hasConceptScore W2896600605C126125632 @default.
• W2896600605 hasConceptScore W2896600605C126322002 @default.
• W2896600605 hasConceptScore W2896600605C16685009 @default.
• W2896600605 hasConceptScore W2896600605C168563851 @default.
• W2896600605 hasConceptScore W2896600605C203014093 @default.
• W2896600605 hasConceptScore W2896600605C2776555147 @default.
• W2896600605 hasConceptScore W2896600605C2778689377 @default.
• W2896600605 hasConceptScore W2896600605C2781087480 @default.
• W2896600605 hasConceptScore W2896600605C2781417161 @default.
• W2896600605 hasConceptScore W2896600605C2908647359 @default.
• W2896600605 hasConceptScore W2896600605C535046627 @default.
• W2896600605 hasConceptScore W2896600605C71924100 @default.
• W2896600605 hasConceptScore W2896600605C99454951 @default.

• next